Vontobel Holding Ltd. Invests $2.43 Million in Acelyrin, Inc. (NASDAQ:SLRN)

Vontobel Holding Ltd. acquired a new stake in shares of Acelyrin, Inc. (NASDAQ:SLRN - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 325,549 shares of the company's stock, valued at approximately $2,429,000. Vontobel Holding Ltd. owned approximately 0.33% of Acelyrin at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Acelyrin in the 4th quarter valued at $84,000. SG Americas Securities LLC acquired a new stake in shares of Acelyrin in the 4th quarter valued at approximately $110,000. Vanguard Group Inc. grew its stake in shares of Acelyrin by 3.8% during the 3rd quarter. Vanguard Group Inc. now owns 3,189,027 shares of the company's stock worth $32,432,000 after purchasing an additional 116,847 shares during the period. Citigroup Inc. acquired a new position in Acelyrin during the third quarter worth about $745,000. Finally, Deutsche Bank AG purchased a new position in Acelyrin in the 3rd quarter valued at approximately $156,000. Institutional investors and hedge funds own 87.31% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Wells Fargo & Company upped their target price on Acelyrin from $11.00 to $13.00 and gave the company an "equal weight" rating in a research note on Thursday, March 21st. HC Wainwright reissued a "buy" rating and set a $28.00 target price on shares of Acelyrin in a research report on Monday, April 1st. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, Acelyrin currently has a consensus rating of "Moderate Buy" and an average target price of $23.67.

Acelyrin Stock Up 2.7 %

Shares of NASDAQ:SLRN traded up $0.13 during trading on Friday, reaching $5.01. The stock had a trading volume of 2,369,138 shares, compared to its average volume of 1,219,191. The stock has a fifty day simple moving average of $7.26 and a two-hundred day simple moving average of $7.83. The firm has a market capitalization of $492.78 million and a price-to-earnings ratio of -0.46. Acelyrin, Inc. has a 52 week low of $4.74 and a 52 week high of $29.88.

Acelyrin (NASDAQ:SLRN - Get Free Report) last posted its earnings results on Thursday, March 28th. The company reported ($0.75) earnings per share for the quarter, beating analysts' consensus estimates of ($1.00) by $0.25. On average, analysts forecast that Acelyrin, Inc. will post -4.18 EPS for the current year.

Insiders Place Their Bets

In other Acelyrin news, CEO Shao-Lee Lin sold 15,701 shares of the company's stock in a transaction that occurred on Tuesday, February 20th. The stock was sold at an average price of $7.60, for a total transaction of $119,327.60. Following the completion of the transaction, the chief executive officer now owns 1,587,335 shares of the company's stock, valued at approximately $12,063,746. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.